Last updated: 2026-10-13 20:38:20. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
MetaVia Inc. (MTVA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1.42, with a market capitalization of $9.29M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.97 to $14.85. This page covers its latest market performance, valuation, price trends and company information.
$9.29M | |
$1.52 | |
$30.25 | |
$0.97 | |
$1.45 | |
61.42K | |
85.66K | |
-- | |
$14.85 | |
$0.97 | |
-- | |
-- |
MetaVia Inc. (MTVA) is trading at $1.43 in after-hours trading as of 2026-10-13 20:06:00, down 1.72% ($0.02) from the regular-session close of $1.45.
After-hours trading shows how investors are pricing MTVA after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, MetaVia Inc. (MTVA) moved from $1.54 to $1.42, representing a decline of 7.53% ($0.12).
The stock traded between $1.33 and $1.65 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 76.83 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.3%
MTVA is currently trading at $1.42, placing it 3.3% of the way from its 52-week low of $0.97 to its 52-week high of $14.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. Vanoglipel (DA-1241) is a novel GPR119 (GPR119) agonist with development optionality as a standalone or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucagon-dependent insulinotropic polypeptide receptor (GIP), and peptide YY.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 8 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of MetaVia Inc. (MTVA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.